Richard D Gelber
Overview
Explore the profile of Richard D Gelber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
208
Citations
15166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pala L, Merlo F, Sala I, Pagan E, Oriecuia C, Specchia C, et al.
J Natl Cancer Inst
. 2025 Mar;
PMID: 40036179
Background: The surrogacy of overall response-rate (ORR) or progression-free survival (PFS) for overall survival (OS) at the trial-level in randomized clinical trials (RCTs) testing antibody-drugs conjugates (ADC) has never been...
2.
Conforti F, Nekljudova V, Sala I, Ascari R, Solbach C, Untch M, et al.
J Clin Oncol
. 2025 Jan;
:JCO2401360.
PMID: 39883887
Purpose: To assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free survival (iDFS) in randomized clinical trials (RCTs) for early breast cancer...
3.
Luen S, Brown L, van Geelen C, Savas P, Kammler R, DellOrto P, et al.
JCO Precis Oncol
. 2025 Jan;
9:e2400599.
PMID: 39854658
Purpose: To investigate whether hormone receptor-positive, human epidermal growth factor receptor 2-low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characteristics. Methods: This study included HR+, HER2-negative...
4.
Azim Jr H, Niman S, Partridge A, Demeestere I, Ruggeri M, Gelber R, et al.
J Clin Oncol
. 2024 Sep;
42(34):4116-4117.
PMID: 39284115
No abstract available.
5.
Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, et al.
J Clin Oncol
. 2024 Sep;
42(31):3643-3651.
PMID: 39259927
JCO The APHINITY trial (ClinicalTrials.gov identifier: NCT01358877) previously demonstrated that pertuzumab added to adjuvant trastuzumab and chemotherapy improved invasive disease-free survival (iDFS) for patients with early human epidermal growth factor...
6.
Pala L, Pagan E, Sala I, Oriecuia C, Oliari M, De Pas T, et al.
EClinicalMedicine
. 2024 Jul;
73:102681.
PMID: 39007061
Background: The outcome of patients with metastatic tumors who discontinued immune checkpoint inhibitors (ICIs) not for progressive disease (PD) has been poorly explored. We performed a meta-analysis of all studies...
7.
Azim Jr H, Niman S, Partridge A, Demeestere I, Ruggeri M, Colleoni M, et al.
J Clin Oncol
. 2024 May;
42(23):2822-2832.
PMID: 38810178
Purpose: We investigated time to pregnancy, efficacy and safety of fertility preservation, and assisted reproductive technologies (ARTs) in women with early hormone receptor-positive breast cancer (BC) desiring future pregnancy. Patients...
8.
Brandao M, Martins-Branco D, De Angelis C, Vuylsteke P, Gelber R, Van Damme N, et al.
Breast Cancer Res Treat
. 2024 Apr;
206(1):207.
PMID: 38592543
No abstract available.
9.
Sala I, Pagan E, Pala L, Oriecuia C, Musca M, Specchia C, et al.
Front Immunol
. 2024 Feb;
15:1340979.
PMID: 38348030
Introduction: There is debate on which are the best surrogate endpoint and metric to capture treatment effect on overall survival (OS) in RCTs testing immune-checkpoint inhibitors (ICIs). Methods: We systematically...
10.
Ganz P, Bandos H, Spanic T, Friedman S, Muller V, Kuemmel S, et al.
J Clin Oncol
. 2024 Feb;
42(11):1288-1300.
PMID: 38301187
Purpose: The OlympiA randomized phase III trial compared 1 year of olaparib (OL) or placebo (PL) as adjuvant therapy in patients with germline , high-risk human epidermal growth factor receptor...